Biotechnology
InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients
SHANGHAI, April 11, 2022 /PRNewswire/ -- InventisBio Co., Ltd., a clinical-stage biotech company based inShanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients. These data are presented in two e-posters at the annual meetin...
2022-04-11 17:37
982
Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL
Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and SUZHOU, China, April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage bio...
2022-04-09 04:00
3887
KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS
SYDNEY, April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce new preclinical data demonstrating the activity of paxalisib in two forms of childhood brain cancer with very high unmet medical need. ...
2022-04-08 20:30
3777
TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
SYDNEY, April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the company's investigational novel drug, EVT801, a selective VEGFR3 ...
2022-04-08 20:00
3523
OliX Pharmaceuticals Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate
* Identified knockdown of target genes for the NASH treatment candidate * Reduction of ALT and AST liver marker levels observed in monkey models * Company to present results at the 2022 Academic Symposium of the Korean Endocrine Society SUWON, South Korea, April 8, 2022 /PRNewswire/ -- OliX ...
2022-04-08 20:00
3339
WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics
SHANGHAI, April 7, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, received an ESG Risk Rating, recognizing it as a "Top Rated" performing company from Sustainalytics as of March, 2022. W...
2022-04-08 08:00
2225
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr.Raffaele Baffa ("Dr. Baffa") has been appointed as...
2022-04-07 23:42
2930
SeekIn Receives CE Mark Approval for LeukoPrint® Molecular Karyotyping Test
First-of-its-Kind Molecular Karyotyping Test SHENZHEN, China, April 7, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for LeukoPrint® Molecular Karyotyping Kit and is now ready to la...
2022-04-07 22:22
2008
REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH
SHANGHAI, April 7, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug development, announced the upcoming presentation of preclinical data of H002, a next-generation epid...
2022-04-07 19:47
1668
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", "the Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced a glob...
2022-04-07 09:09
2072
ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets
BOSTON, April 6, 2022 /PRNewswire/ -- ENSEM Therapeutics Inc. (ENSEM), a Boston -based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CBC group since 2021, the financing is led by GGV Capital, ...
2022-04-07 04:00
2251
Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US
SHENZHEN, China and LEIDEN, Netherlands, April 6, 2022 /PRNewswire/ -- Shenzhen Pregene Biopharma, a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and commercializes innovative medicines and CellPoint, a cell therapy company developing CAR-T therapeuti...
2022-04-06 20:30
2056
Singlera Genomics announces research collaboration with Astellas Pharma pursuing methylation-based tools to better understand biological reactions to pharmaceuticals
SAN DIEGO and TOKYO, April 5, 2022 /PRNewswire/ -- Singlera Genomics Inc. today announced a research collaboration with Astellas Pharma Inc. to develop methylation-based tools to better understand biological reactions to pharmaceuticals using Singlera's mTitan platform. mTitan allows for the int...
2022-04-05 21:56
2039
Vieworks to Make Its Debut at AACR Annual Meeting 2022 with VISQUE InVivo Series
ANYANG, South Korea, April 4, 2022 /PRNewswire/ -- Vieworks will be showcasing its optical in vivo imaging systems at AACR Annual Meeting (April 10-13, booth 2308). VISQUE InVivo Art is Vieworks' premium preclinical optical imaging system for high-sensitivity fluorescent & bioluminescent imaging ...
2022-04-04 21:00
2435
Zhongze Therapeutics Announces Successful Completion Of The First-In-Human Dose Escalation Study of ZZ6398 in Healthy Volunteers
SHANGHAI, April 1, 2022 /PRNewswire/ -- Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders announced today the successful completion of the fi...
2022-04-01 16:55
1832
Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06
SHANGHAI, March 31, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), an innovation-driven biopharmaceutical company focused on the development of innovative drugs for the treatment of chronic hepatitis B and central nervous system diseases, announced dosing of the first particip...
2022-03-31 23:40
1768
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC Grou...
2022-03-31 20:00
1603
CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda
* CBC Group continues to expand its global healthcare ecosystem to fulfil unmet medical needs * Hasten fast-tracks transformative medicines for patients in China SHANGHAI, March 31, 2022 /PRNewswire/ -- Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired a ...
2022-03-31 15:05
2225
LifeTech Scientific Corporation（1302.HK） Announces 2021 Annual Results
Excluding certain non-recurring items, the net profit attributable to owners of the Company increased by 76.8% to RMB 324.0million SHENZHEN, China, March 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventio...
2022-03-31 03:27
3583
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology
- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned up...
2022-03-29 23:00
2203
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
Asia Pacific Defies Global Headwinds: Mastercard Economics Institute 2026 Outlook
[Picked up by 277 media titles]
2025-12-10 09:00